Llwytho...
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia
BACKGROUND: Hydroxyurea (hydroxycarbamide) promotes the production of foetal haemoglobin (HbF) by reactivating gamma‐genes. Evidence has shown clinical benefits of hydroxyurea in people with sickle cell anemia; however, only a few studies have assessed this treatment in people with beta (β)‐thalassa...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cochrane Database Syst Rev |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons, Ltd
2019
|
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6421980/ https://ncbi.nlm.nih.gov/pubmed/30882896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012064.pub2 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|